Market Cap | 86.73M | P/E | - | EPS this Y | 62.80% | Ern Qtrly Grth | - |
Income | -106.81M | Forward P/E | -8.35 | EPS next Y | -19.00% | 50D Avg Chg | 9.00% |
Sales | 14.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 39.00% |
Dividend | N/A | Price/Book | 6.24 | EPS next 5Y | - | 52W High Chg | -23.00% |
Recommedations | 1.20 | Quick Ratio | 6.53 | Shares Outstanding | 59.69M | 52W Low Chg | 223.00% |
Insider Own | 18.03% | ROA | -20.81% | Shares Float | 44.10M | Beta | 1.66 |
Inst Own | 39.80% | ROE | -156.45% | Shares Shorted/Prior | 3.75M/3.01M | Price | 7.10 |
Gross Margin | -63.54% | Profit Margin | - | Avg. Volume | 259,943 | Target Price | 35.33 |
Oper. Margin | -362.02% | Earnings Date | May 3 | Volume | 70,175 | Change | -2.07% |
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Guggenheim | Buy | Apr 15, 24 |
Wedbush | Outperform | Apr 1, 24 |
Wedbush | Outperform | Jan 23, 24 |
Wedbush | Outperform | Dec 19, 23 |
Cantor Fitzgerald | Overweight | Mar 20, 23 |
Chardan Capital | Buy | Mar 17, 23 |
Cantor Fitzgerald | Overweight | Oct 29, 21 |
Chardan Capital | Buy | Oct 27, 20 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
SIEGALL CLAY B | President and CEO President and CEO | Oct 02 | Buy | 5.91 | 169,204 | 999,996 | 319,636 | 10/04/23 |
Turner Bruce | Chief Strategy Offic.. Chief Strategy Officer | Oct 02 | Buy | 5.91 | 42,300 | 249,993 | 42,300 | 10/04/23 |
RAPP MICHAEL | Director Director | Sep 13 | Buy | 17.92 | 45,950 | 823,424 | 182,780 | 09/13/21 |